GlassScriptPhysician profile
Pamela Sw Smith
NPI 1518306448
$26,406.11
in general payments reported to CMS, 2019-2025
18 companies · $1,994 in 2025
The $1,994 reported for 2025 was more than what 76% of Pediatric Endocrinology providers received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40.74 · 2020: $5,089 · 2021: $5,027 · 2022: $6,524 · 2023: $6,353 · 2024: $1,378 · 2025: $1,994.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,267 · Food and Beverage: $699 · Travel and Lodging: $496 · Education: $264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,266.75 |
| Food and Beverage | $699.20 |
| Travel and Lodging | $495.51 |
| Education | $263.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomarin Pharmaceutical INC. | $19,683.69 | 2021-2025 | Voxzogo 1.2mg |
| Ultragenyx Pharmaceutical INC. | $5,847.56 | 2019-2023 | |
| Pfizer INC. | $197.07 | 2019-2025 | |
| Abbvie INC. | $154.87 | 2021-2025 | Lupron Depot |
| Abbott Laboratories | $105.87 | 2021-2023 | Freestyle Libre 3 |
| Tolmar Pharmaceuticals, INC. | $56.03 | 2021 | |
| Arbor Pharmaceuticals, INC. | $48.97 | 2021 | |
| Insulet Corporation | $38.98 | 2021-2023 | Omnipod |
| Xeris Pharmaceuticals, INC. | $35.93 | 2020-2023 | Gvoke Hypopen |
| Rhythm Pharmaceuticals, INC. | $35.26 | 2022-2024 | Imcivree |
| Kyowa Kirin, INC. | $30.93 | 2025 | |
| Ascendis Pharma Endocrinology INC | $29.36 | 2022 | |
| Novo Nordisk INC | $29.13 | 2020-2024 | Sogroya |
| Medtronic Minimed, INC. | $26.51 | 2020 | |
| Lilly USA, LLC | $26.44 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $25.43 | 2023 | Dexcom G6 Transmitter |
| Ipsen Biopharmaceuticals, INC | $19.49 | 2022 | |
| Companion Medical, INC. | $14.59 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pamela Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.